Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Novartis
Gruppo Italiano Malattie EMatologiche dell'Adulto
First Affiliated Hospital of Zhejiang University
Novartis
University of Milano Bicocca
Fundación Teófilo Hernando, Spain
University College, London
M.D. Anderson Cancer Center
University Hospital Southampton NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
University of California, San Diego
University of Pittsburgh
Mirati Therapeutics Inc.
Sanofi
Ann & Robert H Lurie Children's Hospital of Chicago
Chronic Lymphocytic Leukemia Research Consortium